Do we need oncology trials tailored for the elderly or frail?
暂无分享，去创建一个
[1] M. Parmar,et al. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial , 2011, The Lancet.
[2] V. Gebski,et al. International randomized phase III study of capecitabine (Cap), bevacizumab (Bev), and mitomycin C (MMC) in first-line metastatic colorectal cancer (mCRC): Final results of the AGITG MAX trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] R. Goldberg,et al. Colon cancer in older adults. , 2008, Seminars in Oncology.
[4] D. Sargent,et al. Single agent fluorouracil for first-line treatment of advanced colorectal cancer as standard? , 2007, The Lancet.
[5] C. Tournigand,et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] D. Sargent,et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] A. Jemal,et al. Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.